Abstract
Experimental evidences on the adaptive immune response in patients with hereditary hemorragic telagiectasia (HHT) are lacking. Here, we report in 9 patients with HHT a multiple deficit involving the intracellular expression of T helper (h)1-derived cytokines [Interferon (IFN)-γ, Interleukin (IL)-2 and Tumor Necrosis Factor (TNF)-α] and of monocyte- derived TNF-α. On the other hand, percentages of Th2-derived cytokines (IL-4, IL-5 and IL-10) were normal or, in some cases, above normality. Quite interestingly, monocyte-derived IL-10 was detectable in 5 out of 9 patients in a percentage of cells comparable to controls or exceeding normal levels. Taken together, these data point out, in HHT, an ablation of Th1-responses, while Th2-type cytokines are preserved, thus exerting either a suppressive effect on Th1-cells (via IL-4 and IL-10) or an antiinflammatory response on monocyte-derived TNF-α (via IL-10). Furthermore, monocytederived IL-10 may also contribute to the antiinflammatory activity seen in HHT. According to current literature even if patients with HHT do not exhibit certain diseases, such as autoimmune diseases, cancer and abnormal responses to pathogens, the observed immune deficits need to be diagnosed and therapeutically corrected.
Keywords: Cytokines, hereditary hemorrhagic teleangiectasia, monocytes, T-Lymphocytes
Current Pharmaceutical Design
Title: Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations
Volume: 12 Issue: 10
Author(s): F. Resta, V. Triggiani, E. Jirillo, C. Sabba, L. Amati and M. E. Passeri
Affiliation:
Keywords: Cytokines, hereditary hemorrhagic teleangiectasia, monocytes, T-Lymphocytes
Abstract: Experimental evidences on the adaptive immune response in patients with hereditary hemorragic telagiectasia (HHT) are lacking. Here, we report in 9 patients with HHT a multiple deficit involving the intracellular expression of T helper (h)1-derived cytokines [Interferon (IFN)-γ, Interleukin (IL)-2 and Tumor Necrosis Factor (TNF)-α] and of monocyte- derived TNF-α. On the other hand, percentages of Th2-derived cytokines (IL-4, IL-5 and IL-10) were normal or, in some cases, above normality. Quite interestingly, monocyte-derived IL-10 was detectable in 5 out of 9 patients in a percentage of cells comparable to controls or exceeding normal levels. Taken together, these data point out, in HHT, an ablation of Th1-responses, while Th2-type cytokines are preserved, thus exerting either a suppressive effect on Th1-cells (via IL-4 and IL-10) or an antiinflammatory response on monocyte-derived TNF-α (via IL-10). Furthermore, monocytederived IL-10 may also contribute to the antiinflammatory activity seen in HHT. According to current literature even if patients with HHT do not exhibit certain diseases, such as autoimmune diseases, cancer and abnormal responses to pathogens, the observed immune deficits need to be diagnosed and therapeutically corrected.
Export Options
About this article
Cite this article as:
Resta F., Triggiani V., Jirillo E., Sabba C., Amati L. and Passeri E. M., Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361372
DOI https://dx.doi.org/10.2174/138161206776361372 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
BX471: A CCR1 Antagonist with Anti-Inflammatory Activity in Man
Mini-Reviews in Medicinal Chemistry Paracoccidioides spp. and Histoplasma capsulatum: Current and New Perspectives for Diagnosis and Treatment
Current Topics in Medicinal Chemistry Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Current Medicinal Chemistry Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod
Current Drug Targets MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Novel Topical Nanocarriers for Treatment of Psoriasis: An Overview
Current Pharmaceutical Design Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry Tacrolimus Treatment in Myasthenia Gravis
Current Drug Therapy ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome
MicroRNA Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents
Current Medicinal Chemistry Discovery of Small Molecule Inhibitors for Prevention of Complement- Mediated Immune Hemolysis
Drug Design Reviews - Online (Discontinued) Cellular and Molecular Mechanisms Involved in the Action of Vitamin D Analogs Targeting Vitiligo Depigmentation
Current Drug Targets Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets